A Study to Evaluate Corrected QT Interval From Clinical Studies Conducted With Bevacizumab

A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.

NCT00717405 ·Status: COMPLETED ·Phase: PHASE2

A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors

NCT00586092 ·Status: COMPLETED ·Phase: PHASE1

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

NCT00754104 ·Status: WITHDRAWN ·Phase: PHASE1

Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site

NCT00193622 ·Status: COMPLETED ·Phase: PHASE2

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

NCT00915603 ·Status: COMPLETED ·Phase: PHASE2

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

NCT05525767 ·Status: RECRUITING ·Phase: PHASE4

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

NCT00528567 ·Status: COMPLETED ·Phase: PHASE3

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

NCT07299409 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

NCT00054132 ·Status: COMPLETED ·Phase: PHASE2

Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors

NCT00888043 ·Status: COMPLETED ·Phase: PHASE1

An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer

NCT01461044 ·Status: COMPLETED

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

NCT01250379 ·Status: COMPLETED ·Phase: PHASE3

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

NCT03462251 ·Status: COMPLETED ·Phase: PHASE3

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

NCT02254031 ·Status: TERMINATED ·Phase: PHASE1

Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

NCT00374322 ·Status: COMPLETED ·Phase: PHASE3

Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

NCT06998108 ·Status: RECRUITING ·Phase: PHASE3

Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

NCT01880385 ·Status: UNKNOWN ·Phase: PHASE1

A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

NCT02051751 ·Status: COMPLETED ·Phase: PHASE1

Bevacizumab in Multiple Phase I Combinations

NCT00543504 ·Status: COMPLETED ·Phase: PHASE1

Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors

NCT01055795 ·Status: COMPLETED ·Phase: PHASE1

Hypertension in Breast Cancer Patients Receiving Bevacizumab

NCT00674011 ·Status: TERMINATED

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

NCT07018427 ·Status: ACTIVE_NOT_RECRUITING

Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT00079053 ·Status: COMPLETED ·Phase: PHASE1

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

NCT04927884 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

NCT04732598 ·Status: COMPLETED ·Phase: PHASE3